We are pleased to announce that Biocytogen will be attending the 2025 Chinese Antibody Society Annual Meeting (CAS) on May 10, 2025, at the Boston Marriott Cambridge. This event will bring leaders from academia, biotech, and the pharmaceutical industry together to discuss the latest breakthroughs in antibody research. Presentations and speeches will include bispecific antibodies, antibody-drug conjugates, and novel therapeutic approaches. Join us for insightful presentations, engaging discussions, and valuable networking opportunities.
What is the (CAS) Chinese Antibody Society Annual Meeting
The CAS Annual Meeting is hosted by the Chinese Antibody Society, bringing together researchers, experts, and industry professionals to discuss groundbreaking advancements in antibody research and therapeutic development. With the 2025 theme, "New Frontiers in Bispecific Antibodies, Antibody-Drug Conjugates, and Beyond," this year's conference will highlight cutting-edge innovations through insightful presentations, panel discussions, and valuable networking opportunities.
Event Overview
Date: May 10th 8:30 AM EDT
Venue: Boston Marriott Cambridge, 50 Broadway, Cambridge, MA
Event Schedule
The 2025 Chinese Antibody Society (CAS) Annual Conference at Boston Marriott Cambridge will begin at 8:30 AM, featuring expert-led presentations on the latest advances in antibody therapeutics, bispecific antibodies, antibody-drug conjugates, and more. For the full program schedule and detailed session information, please refer to: 2025 CAS.
About BIOCYTOGEN
Biocytogen is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Founded on gene editing technology, Biocytogen leverages genetically engineered proprietary RenMice® platforms for fully human monoclonal antibody discovery, and has established a sub-brand, RenBiologics™, to explore global partnerships for an off-the-shelf library of >400,000 fully human antibody sequences against approximately 1000 targets for worldwide collaboration. Biocytogen pioneered the generation of drug target knock-in humanized models for preclinical research, and currently provides a few thousand off-the-shelf animal and cell models under the company's sub-brand, BioMice™, along with preclinical pharmacology and gene-editing services for clients worldwide. Headquartered in Beijing, Biocytogen has branches in China (Haimen Jiangsu, Shanghai), USA(Boston, San Francisco), and Germany (Heidelberg).
We look forward to seeing you at the Chinese Antibody Society Annual Meeting in Cambridge, MA!
